Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC J9035
    Short Description Bevacizumab injection
    Long Description Injection, bevacizumab, 10 mg
    Pricing indicator 51
    Coverage code C
    ASC payment group code YY
    BETOS2 code O1E
    Action code N
    Type of service 1
    Effective date 2005-01-01
    Date Added 2005-01-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    50242006001 J9035 Bevacizumab injection Avastin GENENTECH, INC. 10 MG 4 1 10 10
    50242006010 J9035 Bevacizumab injection Avastin GENENTECH, INC. 10 MG 4 10 10 100
    50242006101 J9035 Bevacizumab injection Avastin GENENTECH, INC. 10 MG 16 1 40 40
    50242006110 J9035 Bevacizumab injection Avastin GENENTECH, INC. 10 MG 16 10 40 400
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    HCPCS Billing Calculator

    Dosage given to patient (per dose)
    HCPCS Dosage 10 MG
    HCPCS/CPT Billing Units 0.1
    Total doses ordered
    Billing Units 0.1

    Drug Details

    • Bevacizumab injection products are used in combination with other chemotherapy medications to treat certain types of colon and rectal cancer (cancer that begins in the large intestine), non-small cell lung cancer (NSCLC), glioblastoma (a certain type of cancerous brain tumor), renal cell cancer (RCC, a type of cancer that begins in the kidney), cervical cancer (cancer that begins in the opening of the uterus [womb]), and ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), or peritoneal (layer of tissue that lines the abdomen) cancer. Bevacizumab (Avastin) is also used in combination with atezolizumab (Tecentriq) to treat hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery in people who have not previously received chemotherapy. Bevacizumab injection products are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors.